UPenn Observational Research Repository (NCT04715399)

UPenn Observational Research Repository on Neurodegenerative Disease (NCT04715399)

Overview

This repository study at the University of Pennsylvania establishes a comprehensive biobank and longitudinal data repository for neurodegenerative disorders, collecting clinical data, biospecimens, and neuroimaging from patients with Alzheimer's disease, Parkinson's disease, PSP, FTD, ALS, CBS, and related conditions. The repository supports mechanistic research, biomarker discovery, and therapeutic development by providing well-characterized patient cohorts and standardized data collection protocols["@Boxer_2020"].

Study Details

UPenn Observational Research Repository on Neurodegenerative Disease (NCT04715399)

Overview

This repository study at the University of Pennsylvania establishes a comprehensive biobank and longitudinal data repository for neurodegenerative disorders, collecting clinical data, biospecimens, and neuroimaging from patients with Alzheimer's disease, Parkinson's disease, PSP, FTD, ALS, CBS, and related conditions. The repository supports mechanistic research, biomarker discovery, and therapeutic development by providing well-characterized patient cohorts and standardized data collection protocols["@Boxer_2020"].

Study Details

| Parameter | Value |
|-----------|-------|
| NCT Number | NCT04715399 |
| Status | Recruiting |
| Study Type | Observational/Biobank |
| Conditions | PSP, PD, AD, FTD, ALS, CBS, CBD, MSA, PPA |
| Sites | University of Pennsylvania |
| Sponsor | University of Pennsylvania |

Scientific Background

Importance of Biobanking in Neurodegeneration

Neurodegenerative diseases represent a significant and growing health burden, affecting millions of individuals worldwide. The development of effective therapies requires a deep understanding of disease mechanisms, reliable biomarkers for diagnosis and progression tracking, and well-characterized patient cohorts for clinical trials[@Trojanowski_2010]. Biobanks play a critical role in enabling this research by:

Standardized Sample Collection: Biobanks establish standardized protocols for collecting, processing, and storing biospecimens, ensuring quality and comparability across studies.

Longitudinal Data: Repeated assessments over time enable understanding of disease progression and identification of prognostic biomarkers[@Irwin_2018].

Multi-Modal Integration: Combining clinical data, neuroimaging, genetics, and fluid biomarkers provides a comprehensive picture of disease[@Chen_2018].

Research Reproducibility: Well-annotated samples enable replication studies and validation of findings across independent cohorts.

Penn Neurodegeneration Research Program

The University of Pennsylvania has been a leader in neurodegenerative disease research for decades, with major contributions to:

Tau Biology: Understanding tau protein metabolism, phosphorylation, and aggregation mechanisms in PSP, CBD, and AD[@Boxer_2020]

Biomarker Development: Pioneering fluid biomarker development including amyloid and tau in CSF, and neuroimaging biomarkers[@Irwin_2018]

Genetics: Characterizing genotype-phenotype relationships in FTLD, MAPT mutations, GRN, and C9orf72 expansions[@Rohrer_2011]

Clinical Trials: Running landmark trials in AD, PD, PSP, and FTD[@Boxer_2023]

Objectives

Primary Objectives

Secondary Objectives

• Establish standardized assessment protocols for clinical trials
• Enable development of cellular and animal models from patient samples
• Support biomarker discovery and validation studies
• Create reference standards for neuroimaging analysis

Data Collection Protocol

Clinical Assessments

Core Assessment Battery:

• Comprehensive neurological examination
• Detailed medical and family history
• Medication review
• Standardized rating scales specific to each diagnosis

Cognitive Testing:

• Montreal Cognitive Assessment (MoCA)
• Trail Making Test (Parts A and B)
• Stroop Test
• Wisconsin Card Sorting Test
• Domain-specific tests for language, memory, and executive function

• Clinical Dementia Rating (CDR)
• Functional Activities Questionnaire (FAQ)
• Modified Rankin Scale (mRS)
• Lawton-Brody Instrumental ADL Scale

• Neuropsychiatric Inventory (NPI)
• Frontal Behavioral Inventory (FBI)
• Beck Depression Inventory

Neuroimaging Protocol

Magnetic Resonance Imaging (MRI):

• T1-weighted volumetric imaging (MPRAGE/SPGR)
• T2-weighted and FLAIR imaging
• Diffusion tensor imaging (DTI)
• Resting-state functional MRI
• Susceptibility-weighted imaging (SWI)

• [18F]FDG-PET for glucose metabolism
• [11C]PiB or [18F]florbetapir for amyloid PET
• Tau PET ([18F]AV-1451, [18F]MK-6240)
• dopamine transporter imaging (DAT-PET)

• Arterial spin labeling (ASL) for cerebral blood flow
• Magnetic resonance spectroscopy (MRS)
• PET-MRI hybrid scanning

Genetic Testing

Targeted Sequencing:

• Known neurodegenerative disease genes (APP, PSEN1, PSEN2, MAPT, GRN, C9orf72, SNCA, LRRK2, GBA, VCP, TARDBP, FUS)
• APOE genotyping
• Known pathogenic variant screening

• Whole exome sequencing
• Whole genome sequencing (selected cases)
• Genome-wide association studies (GWAS)

Longitudinal Follow-Up

Assessment Schedule:

• Baseline evaluation
• 12-month follow-up
• 24-month follow-up
• Annual thereafter

• Clinical and cognitive assessments
• Sample collection
• Neuroimaging (where indicated)
• Outcome tracking

Biospecimen Collection

Sample Types and Processing

| Sample Type | Volume | Processing | Storage |
|-------------|--------|------------|---------|
| DNA (blood) | 10 ml EDTA | Extracted and quantified | -20°C |
| Plasma | 10 ml EDTA | Centrifugation, aliquot | -80°C |
| Serum | 10 ml SST | Centrifugation, aliquot | -80°C |
| CSF | 10-20 ml | Centrifugation, aliquot | -80°C |
| Skin fibroblast | 3mm biopsy | Culture expansion | Liquid N2 |
| Brain tissue | Autopsy | Dissection, flash freeze | -80°C |

Biomarker Analysis

The repository supports analysis of multiple biomarker classes[@Chen_2018]:

Fluid Biomarkers:

• Beta-amyloid (Aβ42, Aβ40, Aβ40/42 ratio)
• Total tau and phosphorylated tau (p-tau181, p-tau217, p-tau231)
• Neurofilament light chain (NfL)[@Benussi_2022]
• Alpha-synuclein and oligomers
• TDP-43 biomarkers
• YKL-40 (astrocytic marker)
• Neurogranin (synaptic marker)

• Known pathogenic variants
• Polygenic risk scores
• Epigenetic markers

Sample Quality Assurance

• Standardized collection protocols across sites
• Aliquoting to minimize freeze-thaw cycles
• Complete sample annotation in database
• Regular quality control assessments

Research Applications

Mechanistic Studies

The repository enables research into disease mechanisms:

Protein Aggregation Studies:

• Tau isoform analysis and post-translational modifications
• Alpha-synuclein strain characterization
• TDP-43 pathology patterns

• iPSC derivation from patient fibroblasts
• Neuronal differentiation protocols
• Drug screening platforms

• Transcriptomic profiling from blood and tissue
• Single-cell sequencing from brain tissue
• Expression quantitative trait loci (eQTL) analysis

Biomarker Discovery

The well-characterized samples support biomarker research:

Discovery Cohorts: Large numbers of patients with detailed phenotypes enable identification of candidate biomarkers

Validation Studies: Longitudinal samples allow validation of progression markers

Multi-Modal Integration: Combining fluid, imaging, and genetic biomarkers provides comprehensive profiling[@Irwin_2018]

Clinical Trial Support

The repository is essential for clinical trials[@Boxer_2023]:

Patient Recruitment: Well-characterized cohorts enable efficient recruitment

Natural History: Progression data informs trial design and endpoint selection

Biomarker Qualification: Repository samples enable biomarker development for trial enrichment and endpoint selection

Target Validation: Patient samples support mechanistic studies of therapeutic targets

Significance for Precision Medicine

Diagnostic Precision

The repository supports biomarker-driven diagnosis:

• Differentiation between neurodegenerative disease subtypes
• Identification of mimics and diagnostic mimics
• Detection of mixed pathologies

Prognostic Precision

Longitudinal data enables:

• Progression rate prediction
• Identification of rapid vs. slow progressors
• Prediction of specific clinical outcomes

Therapeutic Precision

The repository enables:

• Patient stratification by biomarker profile
• Target engagement studies
• Treatment response monitoring[@Boxer_2023]

Eligibility Criteria

Inclusion Criteria

• [Alzheimer's Disease](/diseases/alzheimers-disease) Parkinson's Disease
• Progressive Supranuclear Palsy
• Corticobasal Syndrome
• Frontotemporal Dementia
• Amyotrophic Lateral Sclerosis
• Multiple System Atrophy
• Related neurodegenerative conditions

Exclusion Criteria

Impact on Neurodegeneration Research

Major Contributions

Penn's neurodegenerative repository has contributed to numerous major discoveries:

Tau Biology Advances: Understanding of tau phosphorylation, aggregation, and spread mechanisms[@Boxer_2020]

Biomarker Development: Validation of CSF and imaging biomarkers for diagnosis and progression[@Irwin_2018]

Genotype-Phenotype Relationships: Characterization of MAPT, GRN, and C9orf72 mutations[@Rohrer_2011]

Clinical Trial Design: Natural history data informing clinical trial endpoints[@Boxer_2023]

Collaborative Research Network

The repository supports:

• Multi-center consortium studies
• Industry partnerships for therapeutic development
• International collaborations for rare variants
• Patient advocacy group partnerships

Related Research Areas

Key Pathways

• [Tau Pathology Mechanisms](/mechanisms/tau-pathology)
• [Alpha-Synuclein Aggregation](/mechanisms/alpha-synuclein-aggregation)
• [TDP-43 Proteinopathy](/mechanisms/tdp-43-proteinopathy)
• [Neurodegeneration Overview](/mechanisms/neurodegeneration-overview)

Related Conditions

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)
• [Frontotemporal Disease](/diseases/frontotemporal-disease)
• [Corticobasal Degeneration](/diseases/corticobasal-degeneration)

Biomarkers

• [Neurofilament Light Chain](/biomarkers/neurofilament-light-chain-nfl)
• [Tau Biomarkers in CSF](/biomarkers/tau-csf)
• [Alpha-Synuclein Biomarkers](/biomarkers/alpha-synuclein-csf)
• [Fluid Biomarkers Overview](/biomarkers/fluid-biomarkers)

Related Studies

• [NIH CTSA PSP Biospecimen Repository](/clinical-trials/nih-ctsa-psp-biospecimen-nct05067192)
• [FTLD Diagnosis Study](/clinical-trials/diagnosing-ftld-nct02964637)
• [Synaptic Loss in MSA](/clinical-trials/synaptic-loss-msa-nct05121012)

See Also

• [Penn FTD Center](https://www.pennmedicine.org/departments-and-centers/department-of-neurology/programs-and-services/frontotemporal-dementia-center)
• [Penn Memory Center](https://www.pennmedicine.org/memorycenter)
• [Parkinson's Disease Research Center](/diseases/parkinsons-disease)
• [CurePSP Foundation](https://www.curepsp.org/)

External Links

• [ClinicalTrials.gov NCT04715399](https://clinicaltrials.gov/study/NCT04715399)
• [University of Pennsylvania Neurology](https://www.pennmedicine.org/departments-and-centers/department-of-neurology)
• [NIH neurodegenerative Disease Research](https://nih.gov)

References